Denka (TSE:4061) Raised Profit Guidance, Is The Valuation Still Justified?

Denka guidance update and what it means for investors

Denka (TSE:4061) raised its operating profit outlook for the first half of the fiscal year ending March 2027, after reporting first quarter results, while guiding to lower net sales and flagging an expected extraordinary loss.

The revised forecast now points to first half net sales of ¥205,000 million and operating income of ¥17,000 million, compared with the previous projection of ¥210,000 million in net sales and ¥12,000 million in operating income.

Management linked this guidance update to steady demand in Electronics & Innovative Products, as well as a temporary positive impact from inventory valuation related to sales price revisions in Polymer Solutions, which are intended to address higher raw material and fuel costs.

At the same time, the company expects demand for Life Innovation products to fall short of initial projections, and it anticipates an extraordinary loss tied to Denka Performance Elastomer LLC, its U.S. subsidiary that has chosen not to restart production for an indefinite period.

See our latest analysis for Denka.

Denka's latest guidance update landed alongside a sharp 1-day share price return of 5.15%, which contrasts with a weaker 90-day share price return of 15.51% and a strong 1-year total shareholder return of 73.40%. This suggests long term momentum with some recent cooling.

If you are looking beyond Denka and want to see where else capital intensive stories are playing out, this is a good moment to check out 36 power grid technology and infrastructure stocks

After Denka's sharp one day move and a share price that still sits below both analyst targets and intrinsic estimates, the real issue is where fair value lies across that spread. How does the current price stack up?

Price-to-earnings of 22.9x for Denka: Is it justified?

On one hand, Denka's shares trade at a discount to both analyst targets and an estimated future cash flow value of ¥5,007.13. On the other, the stock changes hands at a P/E of 22.9x, which screens as expensive against several benchmarks.

The P/E ratio compares the share price to earnings per share and gives a quick sense of how much investors are paying for current profits. For a diversified chemicals group like Denka, P/E often reflects what the market expects from earnings quality, growth and balance sheet strength rather than just recent reported numbers.

Simply Wall St data flags that Denka's 22.9x P/E is higher than its own estimated fair P/E of 21.7x. It is also higher than the peer average of 18.7x and the JP Chemicals industry average of 12.5x. That is a clear premium, which sits awkwardly alongside a value score of 2 out of 6, volatile recent trading, debt that is not well covered by operating cash flow and a dividend that is not well covered by free cash flow.

For investors comparing valuation signals, this kind of P/E premium is the sort of disconnect that can invite a closer look at both earnings forecasts and cash flow strength over time. Explore the SWS fair ratio for Denka

Result: Price-to-earnings of 22.9x (OVERVALUED)

However, the Denka story can quickly change if the extraordinary loss expands or if weaker Life Innovation demand starts to weigh on cash flow support.

Find out about the key risks to this Denka narrative.

Another view on Denka's value

The DCF work paints Denka as undervalued, with the stock at ¥3,596 compared with an estimated future cash flow value of ¥5,007.13, implying a 28.2% gap. That sits uncomfortably next to the rich 22.9x P/E. Is the market underpricing cash flows or overpaying for earnings?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Denka for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 23 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With Denka's mixed signals on valuation and guidance, it makes sense to check the underlying data quickly and decide where you stand. To weigh both the concerns and the potential upside in one place, take a closer look at the 3 key rewards and 4 important warning signs.

Looking for more investment ideas beyond Denka?

Denka is only one part of the opportunity set. If you stop here, you could miss other stocks that better match your goals and risk comfort.

• Hunt for potential bargains that combine quality with attractive pricing through the 23 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies in the 37 dividend fortresses that focus on higher yields.
• Sleep easier at night by checking companies in the 54 resilient stocks with low risk scores that screen for resilience and lower overall risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com